Patents by Inventor Matthias Strieker

Matthias Strieker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240247294
    Abstract: The present invention includes novel systems, methods, and compositions for the enzymatic/chemical production of pseudouridine (?) and its variants, such as N1-methyl-pseudouridine-5?-triphosphate (m1?TP).
    Type: Application
    Filed: March 21, 2024
    Publication date: July 25, 2024
    Inventors: Alexander Koglin, Michael Humbert, Matthias Strieker, Grant Eliason
  • Patent number: 11959117
    Abstract: The present invention includes novel systems, methods, and compositions for the enzymatic/chemical production of pseudouridine (?) and its variants, such as N1-methyl-pseudouridine-5?-triphosphate (m1?TP).
    Type: Grant
    Filed: June 6, 2023
    Date of Patent: April 16, 2024
    Assignee: NATURE'S TOOLBOX, INC.
    Inventors: Alexander Koglin, Michael Humbert, Matthias Strieker, Grant Eliason
  • Publication number: 20230383328
    Abstract: The present invention includes novel systems, methods, and compositions for the enzymatic/chemical production of pseudouridine (?) and its variants, such as N1-methyl-pseudouridine-5?-triphosphate (m1?TP).
    Type: Application
    Filed: June 6, 2023
    Publication date: November 30, 2023
    Inventors: Alexander Koglin, Michael Humbert, Matthias Strieker, Grant Eliason
  • Publication number: 20230151317
    Abstract: The invention includes novel, systems, methods and compositions for the in vitro production of polynucleotides, and in particular the production of mRNA for use in therapeutic applications.
    Type: Application
    Filed: April 16, 2021
    Publication date: May 18, 2023
    Inventors: Michael Humbert, Alexander Koglin, Charlie Villanueva, Matthias Strieker
  • Patent number: 10253099
    Abstract: The present invention relates to conjugates comprising a protein and multivalent cell-penetrating peptide(s), each multivalent cell-penetrating peptide comprising at least two cell-penetrating peptides, wherein the multivalent cell-penetrating peptide(s) is/are covalently attached to the protein. The present invention furthermore relates to a method of generating the conjugates and to their medical uses, in particular their use in the diagnosis, prevention and/or treatment of diseases. The present invention relates to methods of diagnosis, prevention and/or treatment of diseases, comprising administering the conjugates of the invention to a patient.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: April 9, 2019
    Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Matthias Strieker, Walter Mier, Uwe Haberkorn
  • Patent number: 9382294
    Abstract: The discovery of a non-ribosomal peptide synthetase (NRPS) gene cluster in the genome of Clostridium thermocellum that produces a secondary metabolite that is assembled outside of the host membrane is described. Also described is the identification of homologous NRPS gene clusters from several additional microorganisms. The secondary metabolites produced by the NRPS gene clusters exhibit broad spectrum antibiotic activity. Thus, antibiotic compounds produced by the NRPS gene clusters, and analogs thereof, their use for inhibiting bacterial growth, and methods of making the antibiotic compounds are described.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: July 5, 2016
    Assignee: Los Alamos National Security, LLC
    Inventors: Alexander Koglin, Matthias Strieker
  • Publication number: 20160009765
    Abstract: The discovery of a non-ribosomal peptide synthetase (NRPS) gene cluster in the genome of Clostridium thermocellum that produces a secondary metabolite that is assembled outside of the host membrane is described. Also described is the identification of homologous NRPS gene clusters from several additional microorganisms. The secondary metabolites produced by the NRPS gene clusters exhibit broad spectrum antibiotic activity. Thus, antibiotic compounds produced by the NRPS gene clusters, and analogs thereof, their use for inhibiting bacterial growth, and methods of making the antibiotic compounds are described.
    Type: Application
    Filed: February 28, 2014
    Publication date: January 14, 2016
    Applicant: Los Alamos National Security, LLC
    Inventors: Alexander Koglin, Matthias Strieker
  • Publication number: 20150297742
    Abstract: The present invention relates to conjugates comprising a protein and multivalent cell-penetrating peptide(s), each multivalent cell-penetrating peptide comprising at least two cell-penetrating peptides, wherein the multivalent cell-penetrating peptide(s) is/are covalently attached to the protein. The present invention furthermore relates to a method of generating the conjugates and to their medical uses, in particular their use in the diagnosis, prevention and/or treatment of diseases. The present invention relates to methods of diagnosis, prevention and/or treatment of diseases, comprising administering the conjugates of the invention to a patient.
    Type: Application
    Filed: December 4, 2013
    Publication date: October 22, 2015
    Inventors: Matthias STRIEKER, Walter MIER, Uwe HABERKORN
  • Publication number: 20100184189
    Abstract: A simple mutant of the natural asparagine oxygenase comprises at least the amino acids 13 to 318 of the natural asparagine oxygenase AsnO. In this protein according to the present invention, comprising at least the amino acids 13-318 of AsnO D241N, the amino acid residue at position 241 of the natural asparagine oxygenase AsnO is exchanged from aspartate (D) to asparagine (N). The protein according to the present invention, comprising at least the amino acids 13-318 of AsnO D241N, is produced by means of a directed mutagenesis from the AsnO wild type, cloning of this expression plasmid into a vector, transformation of the vector plasmid construction into a host organism and expression of the recombinant protein. The protein according to the present invention is suitable for the chemoenzymatic and enantioselective production of L-threo-hydroxyaspartate from L-aspartate. The protein is substrate-specific and converts quantitatively L-aspartate into L-threo-hydroxyaspartate.
    Type: Application
    Filed: April 7, 2008
    Publication date: July 22, 2010
    Inventors: Mohamed A. Marahiel, Matthias Strieker, Lars-Oliver Essen